TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23480978

Group type: EXPERIMENTAL
Intervention: NBS‐DM2/RW (regular weight)
Number of subjects: 45

Group type: COMPARATOR
Intervention: NBS‐DM2/NW (negligible weight)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pulsed Electromagnetic Fields (PEMF)
Number of subjects: 45
Study: 21712623

Group type: EXPERIMENTAL
Intervention: APF gel application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no APF gel application)
Number of subjects: 0
Study: 19350335

Group type: EXPERIMENTAL
Intervention: Ponseti treatment group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (initial casting and posteromedial release)
Number of subjects: 19
Study: 16689810

Group type: EXPERIMENTAL
Intervention: Alcohol-based gels with varying glycerine concentrations and alcohol grades (70% ethanol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isopropanol-based gel
Number of subjects: 0
Study: 15356963

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no NAC)
Number of subjects: 0
Study: 11210871

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ramosetron 6 microg/kg
Number of subjects: 90
Study: 9313000

Group type: EXPERIMENTAL
Intervention: Bilateral compression ultrasonography
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 1024
Study: 7905376

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml) given from twice to four times daily for 1-8 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Levocabastine eye drops (0.5 mg/ml)
Number of subjects: 174
Study: 3066142

Group type: EXPERIMENTAL
Intervention: Nimodipine (intravenous treatment)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 31815768

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 631

Group type: COMPARATOR
Intervention: Open radical hysterectomy
Number of subjects: 631
Study: 31305115

Group type: EXPERIMENTAL
Intervention: AWARE intervention (group psychotherapy)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 63
Study: 28348182

Group type: EXPERIMENTAL
Intervention: Constrained Condylar Knee (CCK) design
Number of subjects: 170

Group type: COMPARATOR
Intervention: Rotating Hinged (RTH) design
Number of subjects: 170
Study: 26731869

Group type: EXPERIMENTAL
Intervention: Active smokers (n = 27)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Passive smokers (n = 32)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not exposed to tobacco smoke (n = 41)
Number of subjects: 106
Study: 23106907

Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol (mask with positive expiratory pressure of 10 cm H2O, expiratory rib cage compression, coughing, lifting upper limbs, ambulation, starting within 4 hours post-surgery, 3 times daily)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (physiotherapeutic techniques without standardization)
Number of subjects: 123
Study: 22017069

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment with hydrogel patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment without hydrogel patch
Number of subjects: 30
Study: 18435781

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera, EXU) with standard care
Number of subjects: 739

Group type: COMPARATOR
Intervention: Standard care only (Group 2)
Number of subjects: 739
Study: 21395928

Group type: EXPERIMENTAL
Intervention: Handheld computers for Health Management Information System data management
Number of subjects: 9880

Group type: COMPARATOR
Intervention: Quality control laboratory results
Number of subjects: 9880
Study: 15640382

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (three 400-kcal sessions per week at 60% of Vo(2 max))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (three 400-kcal sessions per week at 80% of Vo(2 max))
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 64
Study: 12098040

Group type: EXPERIMENTAL
Intervention: TraumAID computer-generated management plans
Number of subjects: 97
Study: 9688485

Group type: EXPERIMENTAL
Intervention: 1.5 g of cefuroxime intravenously at cord clamping (n = 59)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No prophylaxis (control group, n = 61)
Number of subjects: 120
Study: 7865978

Group type: EXPERIMENTAL
Intervention: Onset hemodialysis (ON-HD) on a low-protein diet
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Early-stage hemodialysis (ES-HD, 1-8 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mid-stage hemodialysis (MS-HD, 9-69 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Advanced-stage hemodialysis (AS-HD, 70-207 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All patients (including ON-HD, ES-HD, MS-HD, AS-HD)
Number of subjects: 96
Study: 2685676

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous oxytocin infusion (every 8 minutes)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Continuous intravenous oxytocin infusion
Number of subjects: 94
Study: 8663

Group type: EXPERIMENTAL
Intervention: bufuralol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 55
Study: 31646599

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29649805

Group type: EXPERIMENTAL
Intervention: CBT with a focus on physical exercise (CBT‐E)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: CBT with a focus on pleasurable, low‐energy and mindful activities (CBT‐M)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 173
Study: 27612574

Group type: EXPERIMENTAL
Intervention: Physical activity intervention consisting of 90min/week of physically active educational lessons, 5min/day of physical activity breaks, and 10min/day of physical activity homework.
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Control group (no physical activity intervention).
Number of subjects: 1129
Study: 25124964

Group type: EXPERIMENTAL
Intervention: Active treatment group using 'TOPHAT655' unit with 21, 5 mW diode lasers (655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments, 67 J/cm² irradiance, 25 minute treatment, 2.9 J dose).
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham treatment group using an identical unit containing incandescent red lights.
Number of subjects: 47
Study: 22448211

Group type: EXPERIMENTAL
Intervention: Pre-ART levels of hsCRP
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Pre-ART levels of D-dimer
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Pre-ART levels of IL-6
Number of subjects: 561
Study: 19330430

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (3-4 days/week)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High aerobic exercise (5-7 days/week)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Minimal aerobic exercise (0-2 days/week, control group)
Number of subjects: 91
Study: 17488308

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg for 4 weeks, titrated to preferred dose of 5, 10, or 20 mg during the next 8 weeks, maintained at preferred dose for 14 weeks)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 611
Study: 15040540

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour intervention in individual patients, in addition to standard of care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study: 11374749

Group type: EXPERIMENTAL
Intervention: In-group comparison with a lower status out-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-group comparison with a higher status out-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated legitimacy of status differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediational analyses
Number of subjects: 0
Study: 9678530

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.1 IU/kg s.c.)
Number of subjects: 15
Study: 7989455

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2729170

Group type: EXPERIMENTAL
Intervention: Aspartame (10 mg aspartame/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29720202

Group type: EXPERIMENTAL
Intervention: Standard acquisition parameters with double dose (0.2 mmol/kg) Gadovist and 4 mm slice thickness.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reduced, single dose of GBCA (n=10), half slice thickness (n=10), or on a 3T scanner (n=10).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3D LGE CMR atrial scar imaging.
Number of subjects: 40
Study: 28705252

Group type: EXPERIMENTAL
Intervention: PGx-guided treatment (n=155)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Treatment as usual (TAU, control group, n=161)
Number of subjects: 316
Study: 26179186

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with defibrillator
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1267
Study: 24119702

Group type: EXPERIMENTAL
Intervention: Probiotics (Golden Bifid, 3.5 g for 3 times per day) for 21 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (conventional treatment and enteral nutrition)
Number of subjects: 52
Study: 20363036

Group type: EXPERIMENTAL
Intervention: All treatments delivered to patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Therapeutic trials with chemotherapy agents
Number of subjects: 42
Study: 17483124

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16478743

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin E (> 400 IU/day)
Number of subjects: 29361

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin E (≥ 10 years of use)
Number of subjects: 29361

Group type: EXPERIMENTAL
Intervention: Supplemental beta-carotene (≥ 2000 microg/day)
Number of subjects: 29361

Group type: COMPARATOR
Intervention: No supplemental vitamin E
Number of subjects: 29361

Group type: COMPARATOR
Intervention: No supplemental beta-carotene
Number of subjects: 29361
Study: 12233984

Group type: EXPERIMENTAL
Intervention: Contingent monetary reinforcement (CM) combined with 21 mg transdermal nicotine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Contingent monetary reinforcement (CM) combined with placebo patch
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noncontingent reinforcement combined with placebo patch
Number of subjects: 42
Study: 10765866

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer materials
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional glass-ionomer material
Number of subjects: 187
Study: 7501142

Group type: EXPERIMENTAL
Intervention: Surgically treated patients (carotid endarterectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall surgical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study: 2176948

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (in vitro measurement without drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population correlation
Number of subjects: 0
Study: 7443023

Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 1 sec
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 5 sec
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 0.5-5.1 sec at random
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Passive trials with no ISI (no stimulus pairing)
Number of subjects: 24
Study: 28785110

Group type: EXPERIMENTAL
Intervention: First-person shooting games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampus-dependent spatial strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3D-platform games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action video game training
Number of subjects: 0
Study: 27157961

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 106
Study: 25711329

Group type: EXPERIMENTAL
Intervention: Arterial elasticity measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline clinical factors
Number of subjects: 0
Study: 23581720

Group type: EXPERIMENTAL
Intervention: B-LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily, bismuth potassium citrate 220 mg b.i.d. for 14 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily for 14 days)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: B-LAL
Number of subjects: 152

Group type: COMPARATOR
Intervention: LAL
Number of subjects: 152
Study: 20581422

Group type: EXPERIMENTAL
Intervention: Early initiation of dialysis (when estimated GFR was 10.0 to 14.0 ml per minute)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Late initiation of dialysis (when estimated GFR was 5.0 to 7.0 ml per minute)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Both early and late initiation groups
Number of subjects: 828
Study: 18430999

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (10, 20, 40, or 60 IU)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 17015418

Group type: EXPERIMENTAL
Intervention: CCC-CPR
Number of subjects: 53
Study: 15022653

Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 42
Study: 11061029

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 33
Study: 9420529

Group type: EXPERIMENTAL
Intervention: 7-day dietary recall (7DDR)
Number of subjects: 1278

Group type: COMPARATOR
Intervention: 24-hour diet recall interview (24 HR)
Number of subjects: 1278
Study: 8272250

Group type: EXPERIMENTAL
Intervention: Duo‐Flux dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Filtral dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: G120 M dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CD 4000 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: T 150 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: F 60 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: G10‐3N dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cuprammonium cellulose hollow‐fibre dialysis
Number of subjects: 37
Study: 2961356

Group type: COMPARATOR
Intervention: Oral Cl2MDP (1600 mg twice daily for 16 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous Cl2MDP (2.5 mg/kg on the first day and 5 mg/kg daily for up to 6 days)
Number of subjects: 17
Study: 31690247

Group type: EXPERIMENTAL
Intervention: Online support group (OSG)
Number of subjects: 58
Study: 29053231

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) administered while experiencing nasal congestion (Cohort 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) administered after treatment with oxymetazoline (Cohort 2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered with nasal congestion (Cohort 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered after recovery from cold symptoms (Cohort 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered with concomitant nasal decongestant (Cohort 2)
Number of subjects: 36
Study: 27307465

Group type: EXPERIMENTAL
Intervention: Educational meetings and peer support (n=646)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Educational meetings, peer support, and access to an outpatient clinic (n=646)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Control group (n=211)
Number of subjects: 857
Study: 24942096

Group type: EXPERIMENTAL
Intervention: Buccal sulcus approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intranasal approach
Number of subjects: 50
Study: 22741255

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study: 20507567

Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study: 18524691

Group type: EXPERIMENTAL
Intervention: 10-session, therapist-administered CBT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4-session, patient-administered CBT
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both CBT versions
Number of subjects: 75
Study: 15727582

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG), a mixture of four probiotic strains, for 4 weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 230
Study: 12046472

Group type: EXPERIMENTAL
Intervention: Wilson frame
Number of subjects: 80

Group type: COMPARATOR
Intervention: genupectoral position
Number of subjects: 80
Study: 9851273

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly i.m. injections for 12 months
Number of subjects: 174

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 12 months
Number of subjects: 174
Study: 7925800

Group type: EXPERIMENTAL
Intervention: Reaching movements (both fast and slow)
Number of subjects: 6
Study: 2643296

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2 by bolus every 3 weeks)
Number of subjects: 77
Study: 766791

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 5 mug/ml
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline 5 mug/ml
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 2
Study: 6105336

Group type: EXPERIMENTAL
Intervention: 30 mg PolyA.PolyU intravenously per week for 6 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal saline intravenously on the same schedule
Number of subjects: 300
Study: 30712716

Group type: EXPERIMENTAL
Intervention: Green tea (4 capsules of 500 mg daily for 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (standard antimicrobial treatment)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Starch (placebo, 4 capsules daily for 3 days)
Number of subjects: 70
Study: 29093283

Group type: EXPERIMENTAL
Intervention: S‐NAC (surgery with N-acetylcysteine 600 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: S‐nonNAC (surgery only)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study: 26208996

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 341

Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 341
Study: 23406981

Group type: EXPERIMENTAL
Intervention: Citicoline (1 g/day) for 12 months
Number of subjects: 347

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 347
Study: 21860040

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 156
Study: 19019899

Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise with heart rate feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise without heart rate feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prescribed intensity aerobic exercise (50% of maximal heart rate reserve)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise
Number of subjects: 48
Study: 18427456

Group type: EXPERIMENTAL
Intervention: Galantamine (maximum dose 16 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 15449272

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open abdominal rectopexy
Number of subjects: 0
Study: 11969062

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines (CAM)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alternative medicines with inhibitory effects on the coagulation cascade
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alternative medicines affecting blood pressure
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alternative medicines affecting cardiac function
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alternative medicines causing sedation
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alternative medicines with potential to alter electrolyte levels
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Herbs recognized to interact with pharmaceuticals
Number of subjects: 496
Study: 9831574

Group type: EXPERIMENTAL
Intervention: Isoenergetic novel diet of milk only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Milk plus one designated food daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional 3.4 MJ diet (control)
Number of subjects: 45